GlassScriptPhysician profile
Troy A Richards
NPI 1386671584
$2,853.72
in general payments reported to CMS, 2019-2025
34 companies · $615 in 2025
The $615 reported for 2025 was more than what 78% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $54.16 · 2021: $240 · 2022: $444 · 2023: $671 · 2024: $552 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $328.10 | 2020-2025 | Enhertu, Injectafer |
| Visionrt, INC. | $259.61 | 2019 | |
| Merck Sharp & Dohme LLC | $218.31 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Profound Medical Corp. | $204.55 | 2022 | |
| Boston Scientific Corporation | $202.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $200.23 | 2022-2025 | Calquence, Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $188.71 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $134.71 | 2023-2025 | |
| Teleflex LLC | $107.30 | 2025 | Barrigel |
| Janssen Biotech, INC. | $107.17 | 2023-2025 | Erleada, Darzalex, Talvey |
| Genentech USA, INC. | $95.49 | 2023-2024 | Tecentriq, Polivy, Phesgo |
| Regeneron Healthcare Solutions, INC. | $77.17 | 2023-2025 | Libtayo |
| Astellas Pharma US INC | $75.86 | 2023-2025 | Vyloy |
| Dendreon Pharmaceuticals LLC | $73.06 | 2022-2025 | Provenge |
| Abbvie INC. | $65.01 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $59.66 | 2023 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $51.15 | 2020-2024 | |
| Karyopharm Therapeutics INC. | $48.96 | 2025 | Xpovio |
| Eisai INC. | $38.85 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.69 | 2023-2024 | Fruzaqla |
| Seagen INC. | $33.35 | 2023 | Adcetris, Tukysa |
| Incyte Corporation | $32.79 | 2021-2024 | Jakafi |
| Blueprint Medicines Corporation | $25.01 | 2023 | Ayvakit |
| Medtronic Minimed, INC. | $21.16 | 2020 | |
| Aveo Pharmaceuticals, INC. | $21.05 | 2025 | |
| Tempus Ai, INC | $20.18 | 2025 | Xt Cdx |
| Beone Medicines USA, INC. | $19.98 | 2025 | Brukinsa |
| Insulet Corporation | $19.47 | 2021 | |
| Acrotech Biopharma INC. | $16.72 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.03 | 2024 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $14.47 | 2024 | |
| Novo Nordisk INC | $13.52 | 2021 | |
| Genmab U.S., INC. | $13.47 | 2023 | Tivdak |
| Mirati Therapeutics, INC. | $13.14 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.